Steroidogenesis in Peripheral and Transition Zones of Human Prostate Cancer Tissue.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
06 Jan 2021
Historique:
received: 30 11 2020
revised: 28 12 2020
accepted: 30 12 2020
entrez: 9 1 2021
pubmed: 10 1 2021
medline: 3 9 2021
Statut: epublish

Résumé

The peripheral zone (PZ) and transition zone (TZ) represent about 70% of the human prostate gland with each zone having differential ability to develop prostate cancer. Androgens and their receptor are the primary driving cause of prostate cancer growth and eventually castration-resistant prostate cancer (CRPC). De novo steroidogenesis has been identified as a key mechanism that develops during CRPC. Currently, there is very limited information available on human prostate tissue steroidogenesis. The purpose of the present study was to investigate steroid metabolism in human prostate cancer tissues with comparison between PZ and TZ. Human prostate cancer tumors were procured from the patients who underwent radical prostatectomy without any neoadjuvant therapy. Human prostate homogenates were used to quantify steroid levels intrinsically present in the tissues as well as formed after incubation with 2 µg/mL of 17-hydroxypregnenolone (17-OH-pregnenolone) or progesterone. A Waters Acquity ultraperformance liquid chromatography coupled to a Quattro Premier XE tandem quadrupole mass spectrometer using a C

Identifiants

pubmed: 33418978
pii: ijms22020487
doi: 10.3390/ijms22020487
pmc: PMC7825320
pii:
doi:

Substances chimiques

Steroids 0
Testosterone 3XMK78S47O
Androstenedione 409J2J96VR
Progesterone 4G7DS2Q64Y
Androsterone C24W7J5D5R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Glaxo SmithKline (GSK)
ID : GSK

Références

Clin Cancer Res. 2011 Sep 15;17(18):5913-25
pubmed: 21807635
Urology. 2009 May;73(5 Suppl):S4-10
pubmed: 19375626
Carcinogenesis. 2015 Jun;36(6):632-8
pubmed: 25870172
J Urol. 2002 Jul;168(1):9-12
pubmed: 12050481
Prostate. 2016 May;76(6):575-87
pubmed: 26841972
Cancer Res. 2008 Aug 1;68(15):6407-15
pubmed: 18676866
Chem Biol Interact. 2015 Jun 5;234:332-8
pubmed: 25514466
Cancer Res. 2011 Oct 15;71(20):6503-13
pubmed: 21868758
J Steroid Biochem. 1989 Aug;33(2):155-63
pubmed: 2475672
Clin Chim Acta. 2008 May;391(1-2):36-40
pubmed: 18328817
BMC Med. 2015 Sep 01;13:206
pubmed: 26329698
Cancer Res. 2010 Feb 1;70(3):1256-64
pubmed: 20086173
Endocrinology. 2014 Feb;155(2):358-69
pubmed: 24265454
FASEB J. 2010 Mar;24(3):769-77
pubmed: 19901020
Endocr Relat Cancer. 2009 Dec;16(4):1139-55
pubmed: 19608712
J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:436-44
pubmed: 25201454
BMC Cancer. 2013 Jul 29;13:362
pubmed: 23890084
Clin Cancer Res. 2011 Sep 15;17(18):5844-9
pubmed: 21705451
Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13728-33
pubmed: 21795608
Endocr Rev. 2004 Apr;25(2):276-308
pubmed: 15082523
Steroids. 2012 Jun;77(7):719-26
pubmed: 22503713
Cancers (Basel). 2018 Sep 20;10(10):
pubmed: 30241348
Prostate. 2015 Feb;75(2):183-90
pubmed: 25327466
Int Urol Nephrol. 1995;27(3):231-43
pubmed: 7591584
Cancer Res. 2008 Jun 1;68(11):4447-54
pubmed: 18519708
Transl Androl Urol. 2013 Sep;2(3):212-227
pubmed: 25379460
J Steroid Biochem Mol Biol. 2013 Sep;137:176-82
pubmed: 23770321
Cancer Res. 2012 Dec 1;72(23):6142-52
pubmed: 22971343
Mol Cell Endocrinol. 2012 Sep 5;360(1-2):3-13
pubmed: 22453214
Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):243-58
pubmed: 18471783
Semin Oncol Nurs. 2011 Nov;27(4):241-50
pubmed: 22018403
Cell. 2013 Aug 29;154(5):1074-1084
pubmed: 23993097
Transl Oncol. 2019 Jan;12(1):43-48
pubmed: 30265975
Clin Cancer Res. 2013 Jul 1;19(13):3353-9
pubmed: 23470964
Korean J Urol. 2011 Jul;52(7):494-7
pubmed: 21860772
Prostate. 2014 Feb;74(3):235-49
pubmed: 24150795
Am J Pathol. 2012 Sep;181(3):1078-87
pubmed: 22796438
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 1;902:84-95
pubmed: 22818945
Carcinogenesis. 2006 Feb;27(2):216-24
pubmed: 16123118
Endocrinol Metab Clin North Am. 2011 Sep;40(3):565-75, viii-ix
pubmed: 21889721
Sci Rep. 2013;3:1528
pubmed: 23524847
J Investig Med. 2012 Feb;60(2):504-7
pubmed: 22064602
BMC Cancer. 2014 Sep 26;14:717
pubmed: 25256077
Clin Cancer Res. 2014 Nov 1;20(21):5547-57
pubmed: 24771644

Auteurs

Subrata Deb (S)

Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, 18301 N. Miami Avenue, Miami, FL 33169, USA.

Mei Yieng Chin (MY)

The Vancouver Prostate Centre, Vancouver General Hospital, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.

Steven Pham (S)

The Vancouver Prostate Centre, Vancouver General Hospital, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.

Hans Adomat (H)

The Vancouver Prostate Centre, Vancouver General Hospital, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.

Antonio Hurtado-Coll (A)

The Vancouver Prostate Centre, Vancouver General Hospital, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.

Martin E Gleave (ME)

The Vancouver Prostate Centre, Vancouver General Hospital, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.

Emma S Tomlinson Guns (ES)

The Vancouver Prostate Centre, Vancouver General Hospital, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH